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Introduction: Survival after extrapleural pneumonectomy (EPP) is
variable in patients with malignant pleural mesothelioma (MPM),
and there are no validated prognostic factors that could be used
preoperatively. We investigated the calretinin and D2-40 expression
and the neutrophil-to-lymphocyte ratio (NLR), an index of systemic
inflammation as potential preoperative prognostic factors.
Methods: Consecutive patients who underwent EPP were included
in this retrospective study. Potential prognostic factors such as age,
gender, histological subtype, baseline laboratory parameters includ-
ing NLR, and immunohistochemical staining for calretinin and
D2-40 were evaluated. Overall survival (OS) from the date of
surgery was determined by the Kaplan-Meier method. The prognos-
tic value of the variables was examined using Cox regression, and
significant factors (p 0.05) were entered into a multivariate model
to determine their independent effect.
Results: A total of 85 patients were included: median age 58 years;
80% men; 77% epithelial and 23% biphasic MPM. The median OS
was 19.7 months. The following variables were predictive of longer
OS: female gender (p  0.02), epithelial subtype (p  0.04), low
NLR (p  0.01), and high calretinin score (p  0.001). In a
multivariate analysis, only NLR 3 (hazard ratio 1.79; 95% confi-
dence interval: 1.04–3.07; p  0.04) and calretinin score 33
versus more than 67% (hazard ratio 4.72; 95% confidence interval:
1.97–11.32; p  0.01) remained independent predictors. The addi-
tion of calretinin score increased the explained variation by 10.1%.
Conclusions: Both low calretinin expression and high NLR were
independently associated with poor prognosis in patients with MPM
undergoing EPP, and the calretinin score seemed to improve the
accuracy of the prognostic model.
Key Words: Malignant pleural mesothelioma, Calretinin, Neutro-
phil-to-lymphocyte ratio, Prognosis.
(J Thorac Oncol. 2011;6: 1923–1929)
Malignant pleural mesothelioma (MPM) is an aggressiveand difficult-to-treat tumor. It is caused by the carcino-
genic effect of asbestos on the mesothelium surrounding the
serosal cavities in the thorax. Because of the long latency
period between asbestos exposure and the occurrence of
MPM, the incidence of the disease continues to increase even
in countries where a ban on the use of asbestos is in place.1
When the ongoing heavy use in some developing countries is
considered, the disease is expected to remain a growing
global problem for many decades to come.1
The standard of care for patients with MPM has yet
to be established.2,3 Although therapy has improved incre-
mentally over the past 20 years, the disease remains almost
invariably fatal with a median survival ranging from 7 to
24 months.4,5 Extrapleural pneumonectomy (EPP) has
been performed increasingly over the past two decades as
an option for some patients with MPM. Some patients
survive long periods after surgery, but in others the disease
course does not seem to be affected by a radical (surgical)
approach. To improve outcomes, many institutions now
favor trimodality therapy combining EPP with chemother-
apy and/or radiotherapy.6–11
The significant morbidity and mortality associated with
EPP require careful selection of patients.2,3,12,13 To qualify for
the procedure, good performance status, adequate organ func-
tion, and a potentially resectable tumor are the most frequent
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criteria that must be met. Histological subtype and extrapleu-
ral nodal status have been consistently identified as indepen-
dent prognostic factors in determining survival in patients
undergoing trimodality treatment.14–16 Despite these prog-
nostic indicators, the preselection of patients coupled with an
absence of randomized controlled trials make it difficult to
assess the benefits of EPP. Besides histological subtype, there
remains a lack of accurate prognostic factors to identify the
patients more likely to benefit from EPP before the surgery is
performed.
Immunohistochemical (IHC) assessment in the diagno-
sis of MPM is well established. A panel of positive and
negative IHC markers for MPM is needed for the diagnosis as
recommended by the International Mesothelioma Panel.17
Two of the mesothelial-related markers commonly used in
the diagnostic setting include calretinin and D2-40,17,18 but
their prognostic role is yet to be established.
Recently, we identified the neutrophil-to-lymphocyte
ratio (NLR) as an independent prognostic factor for patients
with MPM undergoing systemic therapy.19 As an easily
reproducible and inexpensive marker, NLR, a measure of
systemic inflammation, has the potential to aid in the man-
agement of patients with MPM.
In this study, we have retrospectively assessed the
prognostic values of calretinin and D2-40 IHC expression and
NLR in predicting outcome following EPP. We also explored
the relationship between pathological stage and the systemic
inflammatory status indicated by NLR.
PATIENTS AND METHODS
Consecutive patients with MPM who underwent EPP at
Royal Prince Alfred and Strathfield Private Hospitals, Syd-
ney, Australia, from 1994 to November 2009 were included
in the study. The patient selection for EPP was as described
previously.14 The demographic and treatment details of the
patients were kept in a prospectively collected database. This
study was approved by the Human Research Ethics Commit-
tees at the Sydney South West Area Health Service—Con-
cord Repatriation General Hospital Zone.
The histological diagnosis of MPM was confirmed by
two pathologists. Diagnostic IHC evaluation included a stan-
dard panel of antibodies (calretinin, BG-8, and CD15), as
described previously,18 and D2-40. The histological subtypes
were assigned in accordance to the World Health Organiza-
tion criteria and recommendations.20 Pathological stage was
determined according to the American Joint Committee on
Cancer Staging System.21
Full blood counts were collected the day before EPP as
part of the preoperative assessment. Hemoglobin (Hb), platelet
count, white cell count (WCC), and its differential counts were
recorded. According to previous publications, Hb difference
defined as the difference relative to 160 g/liter in men and 140
g/liter in women was dichotomized to 10 g/liter versus 10
g/liter22; platelet count into 400  109/liter versus 400 
109/liter,23 and WCC into 8.3  109/liter versus 8.3 
109/liter.24 The NLR was defined as the absolute neutrophil
count divided by the absolute lymphocyte count.
Archival formalin-fixed, paraffin-embedded tissues
from the EPP procedure were retrieved. Serial 4-m-thick
paraffin sections of the tumor underwent IHC labeling for
calretinin and D2-40. Primary rabbit anticalretinin antibody
(dilution 1:2000; Invitrogen, Camarillo, CA) and primary
anti-D2-40 monoclonal antibody (dilution 1:100; Signet)
were applied to incubate the sections overnight at 4°C after
citric acid retrieval (1:10 dilution of 0.1 M citrate buffer, pH
6.0) in a microwave. All primary antibodies were diluted in
10% normal goat serum. The reaction with calretinin was
developed with the Novocastra Polymer System (Leica Bio-
systems Newcastle Ltd, Newcastle Upon Tyne, UK), using
the Liquid DAB and Substrate Chromogen System (Dako
North America Inc, Carpinteria, CA), whereas the reaction
with D2-40 was developed with the EnVision  Dual Link
System (Dako), using the DAB Substrate Kit (Cell Marque,
Rocklin, CA). For the quantitative evaluation of IHC scores
of calretinin and D2-40, the percentage of cells labeled by the
antibodies was recorded, irrespective of the intensity, result-
ing in a percentage score that ranged from 0 to 100%. All
sections were assessed by two independent examiners in a
blinded fashion. If there were scoring discrepancies of more
than 10%, sections were reviewed jointly and a consensus
reached.
Statistical Analysis
Overall survival (OS) was calculated from the date of
EPP and the date of death or last follow-up. Patients were
censored at last follow-up if still alive or lost to follow-up.
The prognostic value of the variables was examined using
univariate Cox regression with either continuous (age, NLR,
calretinin, and D2-40 scores) or categorical (gender, histo-
logical subtype, Hb difference, platelet count, and WCC)
variables. NLR was log transformed. Variables with p value
less than 0.05 were considered statistically significant and
Kaplan-Meier curves examined. Individually significant vari-
ables were entered into a multivariate model together with the
established risk factors: age, gender, and histological subtype.
The relationship between pathological stage and NLR was
assessed using Spearman’s correlation. These analyses were
performed using SPSS for Windows version 17.0.
The additive discriminatory accuracy of calretinin and
NLR, on top of the standard age/gender/subtype variables,
was investigated using the method of Schemper and Hender-
son,25 implemented in the R package surev.26 Briefly, this
was assessed by calculating the mean absolute difference
between observed survival outcome and the model predic-
tions. Explained variation was also computed and represents
a measure equivalent to R2 in linear regression. Standard
errors were obtained by bootstrapping 200 samples.
RESULTS
Patient Cohort
Eighty-five patients underwent EPP over the study
period, and archival tissue from 80 patients was available for
further study. The baseline characteristics of this cohort and
the epithelial and biphasic subgroups are summarized in
Table 1. Briefly, for the entire cohort: median age 58 years;
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80% men; 77% epithelial MPM, and 23% biphasic MPM;
and median OS 19.7 months (95% confidence interval: 13.8–
25.6 months). Nineteen patients underwent neoadjuvant che-
motherapy: 8 with carboplatin and pemetrexed, 10 with
cisplatin and pemetrexed, and 1 with carboplatin and vinore-
lbine. Two of them attained complete response with no tumor
being demonstrable in the surgically excised tissue.
There was a wide range of calretinin and D2-40 ex-
pression. For calretinin, the median score was 57.5% (range:
0–100%) with a median score of 60% for epithelial and 30%
for biphasic subtype. For D2-40, the median score was 50%
(range 2–95%) with a median score of 58% for epithelial and
9% for biphasic subtype.
Univariate and Multivariate Analysis for
Prognostic Factors
In the univariate analysis, gender and histological sub-
type, NLR, calretinin, and D2-40 score were all significant
prognostic factors. Including these significant variables with
age in a multivariate Cox regression model, NLR, and calre-
tinin score remained independent prognostic factors (Table
2). After converting NLR and calretinin score into categorical
variables (NLR categorized into 3 and 3 and calretinin
score into 33%, 34–67%, and 67%), they remained
significant in the multivariate model along with age, gender,
and histological subtype (Table 3).
Kaplan-Meier Curves
Figure 1A shows the Kaplan-Meier curve for NLR:
median OS of 26.7 months for NLR less than 3 and 12.6
months for NLR 3 (p  0.006). Figure 1B shows the
Kaplan-Meier curve for calretinin score: median OS of 35.8
months for calretinin score more than 67%; 14.5 months for
calretinin score of 34 to 67%; and 6.9 months for calretinin
score 33% (p  0.001).
With the aim of developing a more accurate prognostic
tool, we then combined NLR and calretinin scores: category
1  NLR less than 3 and calretinin more than 67%; category
2 NLR less than 3 and calretinin67%; or NLR more than
3 and calretinin more than 33%; category 3  NLR 3 and
calretinin 33%. Figure 1C demonstrates the Kaplan-Meier
curve for this composite score and shows that the median OS
was 48.7 versus 15.9 versus 6.4 months for category 1, 2, and
3, respectively.
Discriminative Accuracy
The predicted inaccuracy for a model without predic-
tors (independent variables) is 0.328 for this dataset, repre-
senting the maximum level of inaccuracy to predict OS.
Using NLR in addition to the standard variables had only a
minor impact on the predictive inaccuracy (reduced from
0.309 to 0.300). Modest improvement was seen when calre-
tinin was incorporated into the model, with a slight improve-
ment again seen for the composite score. This final model
also had the highest explained variation (Table 4).
Relationship Between Stage and NLR
The mean NLR for stage I disease was 2.4 (standard
deviation [SD]: 0.7); 2.9 (SD: 1.5) for stage II; 3.7 (SD: 2.1)
TABLE 1. Baseline Characteristics of the Extrapleural
Pneumonectomy Cohort
Variables
Total
Cohort
(n  85)
Epithelial
Subgroup
(n  65)
Biphasic
Subgroup
(n  20)
Age (yr)
Median (range) 58 (22–74) 58 (22–70) 60.5 (43–74)
Gender
Male 68 49 19
Female 17 16 1
Laterality
Right 49 40 9
Left 36 25 11
Hb difference
(g/liter)
10 21 18 3
10 63 46 17
Missing 1 1 0
Baseline platelet
counts
(109/liter)
400 63 48 15
400 20 15 5
Missing 2 2 0
Baseline white
cell count
(109/liter)
8.3 48 37 11
8.3 36 27 9
Missing 1 1 0
Pathological stage
Complete
response
2 1 1
I 5 4 1
II 18 15 3
III 54 43 11
IV 6 2 4
Neutrophil-to
-lymphocyte
ratio
Median (range) 3 (1–13.9) 2.9 (1.2–7.9) 3.4 (1–13.9)
3 40 33 7
3 44 31 13
Missing 1 1 0
Calretinin score
(%)a
Median (range) 57.5 (0–100) 60 (0–100) 30 (0–75)
33% 22 11 11
34–67% 29 23 6
67% 29 27 2
Missing 5 4 1
D2-40 score (%)a
Median (range) 50 (2–95) 58 (3–95) 9 (2–53)
Overall survival
(mo)a
Median (95% CI) 19.7 (13.8–25.6) 23.2 (12.8–33.5) 12.2 (1.1–23.2)
a Statistically different between epithelial and biphasic MPM (defined as p  0.05
in Kaplan-Meier method for survival and independent t test for calretinin and D2-40).
Hb, hemoglobin; CI, confidence interval; MPM, malignant pleural mesothelioma.
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for stage III; and 3.1 (SD: 0.9) for stage IV. The Spearman’s
correlation between NLR and pathological stage was 0.25
(p  0.03).
DISCUSSION
The effectiveness of EPP in extending the survival of
patients with MPM remains controversial.27 Several criteria
are used to select patients for this procedure, but even in this
preselected patient population, survival after EPP is highly
variable. Currently, there is no method to identify the sub-
population of patients most likely to benefit from the radical
approach.
Unlike other solid tumors where tumor grade is rou-
tinely reported and often provides important prognostic in-
formation, there is currently no consensus as to how best to
assign tumor grade in MPM.28 It is not routinely reported in
clinical practice or clinical trials. Renewed interest in tumor
grade in MPM has followed a large population-based study
using the Surveillance, Epidemiology, and End Results data-
base, which demonstrated tumor grade to be a significant
prognostic factor.29 However, because of the retrospective
nature of the study, and the absence of pathology review, the
definition of the tumor grade was criticized, and it is worth
noting that 90% of the patients in the study did not have an
assigned grade.29 Cunto-Amesty et al.30 presented a pilot
study of reporting tumor grade using a morphologicallybased
grading system, examining the cellular and architectural mor-
phology, necrosis, and mitotic rates. They found that well-
differentiated tumors trended toward having longer survival
than those with poorly differentiated tumors in 20 cases of
stage II patients with MPM who were treated with EPP.30
Similarly, Takeshima et al.31 demonstrated the prognostic
role of the tumor grade in 53 patients with epithelial MPM
and found the expression of calretinin (scored from 0 to 3)
to be highly correlated with tumor differentiation, i.e., higher
calretinin scores in the more differentiated tumors. As such,
the calretinin scores may reflect the grading of the MPM
tumors.
In this study, we used a retrospective series of 85
patients with MPM who underwent EPP to identify potential
factors that could be used to stratify patients before the
TABLE 2. Univariate and Multivariate Analysis for Prognostic Factors
Univariate Analysis Multivariate Analysis
HR 95% CI p HR 95% CI p
Age (yr)a 1.14 0.89–1.48 0.30 0.88 0.63–1.23 0.44
Gender
Male 1 (reference)
Female 0.44 0.21–0.90 0.02 0.47 0.20–1.10 0.82
Histological subtype
Epithelial 1 (reference)
Biphasic 1.80 1.04–3.11 0.04 0.84 0.41–1.71 0.62
Haemoglobin difference
10 1 (reference)
10 1.64 0.91–2.97 0.10
White cell count
8.3 1 (reference)
8.3 1.49 0.91–2.44 0.11
Platelet count
400 1 (reference)
400 1.27 0.72–2.24 0.42
NLR logb 4.64 1.66–12.95 0.01 3.24 1.06–10.71 0.04
Calretinin score (%)a 0.83 0.75–0.92 0.001 0.86 0.76–0.98 0.03
D2-40 score (%)a 0.89 0.81–0.98 0.02 0.95 0.85–1.06 0.35
a Increment of 10 units.
b Increment of 1 unit.
HR, hazard ratio; CI, confidence interval; NLR, neutrophil-to-lymphocyte ratio.
TABLE 3. Multivariate Analysis After Categorizing Variables
HR 95% CI p
Agea 0.81 0.57–1.16 0.25
Gender
Male 1 (reference)
Female 0.43 0.18–1.03 0.06
Histological subtype
Epithelial 1 (reference)
Biphasic 0.77 0.38–1.56 0.47
NLR
3 1 (reference)
3 1.79 1.04–3.07 0.04
Calretinin
33% 4.72 1.97–11.32 0.01
34–67% 1.57 0.83–2.97 0.17
67% 1 (reference)
a Increment of 10 yr.
HR, hazard ratio; CI, confidence interval; NLR, neutrophil-to-lymphocyte ratio.
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radical surgery. We found that the extent of the calretinin
labeling was associated with OS, with more extensive calre-
tinin labeling linked to longer OS. Our results further suggest
that the tumor differentiation indicated by calretinin labeling
in patients with resectable MPM provides important informa-
tion. To the best of our knowledge, this is the first report to
implicate calretinin as a prognostic factor. Pathological stag-
ing was deliberately not accounted for in the multivariate
model as it often cannot be accurately assessed preoperatively
and as a result is not available for consideration. Even taking
pathological staging into account (data not shown), calretinin
score remained independently associated with prognosis.
In this study, calretinin score was assessed by the
extent of labeling (i.e., the percentage of labeled cells)
regardless of the intensity. There were multiple reasons for
not considering intensity in the score: assessment of inten-
sity can be subjective and several factors can alter the
outcome such as uneven thickness of the section created by
differing sharpness of the blade of the microtome; inconsisten-
cies of manual incubation times between batches of the exper-
iments; and degree of background staining. Our proposed score
is easy to adopt in the daily clinical practice of a diagnostic
pathologist, particularly when calretinin is routinely applied in
the diagnosis of MPM.
FIGURE 1. A, Kaplan-Meier curve for overall survival stratified by neutrophil-to-lymphocyte ratio (NLR). Median overall sur-
vival was 26.7 months versus 12.6 months for NLR 3 and 3, respectively. B, Kaplan-Meier Curve for overall survival strati-
fied by calretinin. Median overall survival was 35.8 versus 14.5 versus 6.9 months for calretinin scores more than 67%, 34 to
67%, and 33%, respectively. C, Kaplan-Meier curve for overall survival stratified by the composite score. Median overall sur-
vival was 48.7 months versus 15.9 months versus 6.4 months for categories 1, 2, and 3 respectively. Category 1  NLR less
than 3 and calretinin more than 67%; category 2  NLR less than 3 and calretinin 67% or NLR more than 3 and calretinin
more than 33%; and category 3  NLR 3 and calretinin 33%.
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From the literature, it is clear that even a significant
prognostic factor with a large hazard ratio may not contribute
to a meaningful improvement in the discriminative accu-
racy.25 We found when calretinin score was considered in
addition to the traditional prognostic factors of age, gender,
and histological subtype, the explained variation in survival
was increased by 10.1%. As such, it seemed that calretinin
score has additional prognostic value for OS in patients with
MPM undergoing EPP. Given calretinin is routinely used in
the diagnosis of MPM and the proposed scoring method is
simple, we believe that there is value in using calretinin score
in clinical practice.
NLR has been implicated as a prognostic factor in
several tumor types, including MPM.19 It is an inflammation-
based score, and an elevated NLR is thought to reflect an
exaggerated systemic inflammatory response. In our previous
report, an elevated NLR (defined as 5) predicted shorter
survival in patients with unresectable MPM treated with
systemic therapy.19 In this study on resectable patients treated
with EPP, preoperative NLR was also independently associ-
ated with prognosis; after adjusting for known prognostic
factors such as histological subtype, age, and gender, patients
with NLR less than 3 had longer OS than those with NLR3
(p  0.04). The cutoff of 3 for NLR was chosen in this study
as it is the median value for this series, and only 13% of
patients had a NLR of more than 5. However, when consid-
ered in the prognostic model, neither NLR alone nor the
combination of calretinin score and NLR was significantly
superior to calretinin score alone in discriminative accuracy.
Despite the lack of NLR to increase the discriminative
accuracy, systemic inflammation remains an important factor
to consider in patients with resectable MPM. The hypothesis
that systemic inflammation becomes more exaggerated as the
disease progresses is supported by the fact that the median
NLR in this EPP cohort was 3, whereas the median NLR in
the patients with unresectable MPM treated with systemic
therapy in our previous series was 5.19 This is also reflected
in the positive correlation between increasing NLR and pro-
gressive stage in our study.
This study has its limitations. Despite the promising
results on the prognostic role of the calretinin score in the
patients undergoing EPP, this study is retrospective. As such
it suffers from the inherent problems associated with retro-
spective analysis. Although the histological subtype was
taken into account when performing the multivariate analysis,
there was an absence of the sarcomatoid subtype of MPM in
our series. This highlights the other limitation of the study as
our study focused on a specific subset of patients with MPM
who were eligible for EPP, which renders the results less
generalizable to the whole MPM population. Nevertheless,
the study cohort is representative of the typical patient group
that is suitable for EPP. Our results need validation in an
independent series of patients, preferably in a prospective
fashion. This should be done in all patients presenting with
MPM to confirm the prognostic value of calretinin in all
patients with MPM.
Furthermore, even though calretinin score and NLR
were significant independent factors, together with the tradi-
tional factors of histological subtype, age, and gender, they
only explained 16.8% of the variation in this cohort’s sur-
vival. This is a potent reminder that further advance in our
knowledge of the biology of MPM is urgently required to
explain major survival differences.
In conclusion, this study has addressed the need for
preoperative factors that can better predict outcome of pa-
tients with MPM undergoing EPP. Extent of calretinin label-
ing seems to be a useful factor to consider preoperatively.
With a median survival of 6.9 months for patients with a
calretinin score of less than 33%, one may argue that surgery
does not seem to benefit such patients and this may reflect the
more aggressive biology of a tumor that is not altered by
the treatment. Given that calretinin is routinely used for the
pathological diagnosis of MPM, we believe that it is rela-
tively easy to prospectively confirm the prognostic value of
this marker, in particular, in an adequately sized diagnostic
biopsy in advance of EPP.
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